Recent publications published by researchers at the MRC WIMM.
SFX-01 is therapeutic against myeloproliferative disorders caused by activating mutations in Shp2.
Cho H-J. et al, (2025), EMBO Mol Med, 17, 2115 - 2136
Recent publications published by researchers at the MRC WIMM.
Cho H-J. et al, (2025), EMBO Mol Med, 17, 2115 - 2136